Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Brief Summary: The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in patients with advanced lung cancer.


Options:
A: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab | Arm Label: Arm B: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: Arm C: Nivolumab + Platinum doublet chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Carboplatin, Drug: Cisplatin, Drug: Gemcitabine, Drug: Pemetrexed, Drug: Paclitaxel | Arm Label: Arm D: Platinum doublet chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Cisplatin, Drug: Gemcitabine, Drug: Pemetrexed, Drug: Paclitaxel | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab, Arm B: Nivolumab + Ipilimumab, Arm C: Nivolumab + Platinum doublet chemotherapy | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Arm B: Nivolumab + Ipilimumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm C: Nivolumab + Platinum doublet chemotherapy, Arm D: Platinum doublet chemotherapy | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Arm C: Nivolumab + Platinum doublet chemotherapy, Arm D: Platinum doublet chemotherapy | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Arm C: Nivolumab + Platinum doublet chemotherapy, Arm D: Platinum doublet chemotherapy | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Arm C: Nivolumab + Platinum doublet chemotherapy, Arm D: Platinum doublet chemotherapy | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm C: Nivolumab + Platinum doublet chemotherapy, Arm D: Platinum doublet chemotherapy
B: Arm Label: Arm A (Atezolizumab+Paclitaxel+Carboplatin); Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Drug: Carboplatin, Drug: Paclitaxel | Arm Label: Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin); Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Drug: Bevacizumab, Drug: Carboplatin, Drug: Paclitaxel | Arm Label: Arm C (Bevacizumab+Paclitaxel+Carboplatin); Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Carboplatin, Drug: Paclitaxel | Intervention Type: DRUG; Name: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody; Assigned to Arm(s): Arm A (Atezolizumab+Paclitaxel+Carboplatin), Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin), Arm C (Bevacizumab+Paclitaxel+Carboplatin) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm A (Atezolizumab+Paclitaxel+Carboplatin), Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin), Arm C (Bevacizumab+Paclitaxel+Carboplatin) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm A (Atezolizumab+Paclitaxel+Carboplatin), Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin), Arm C (Bevacizumab+Paclitaxel+Carboplatin)
C: Arm Label: (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Cisplatin, Drug: Gemcitabine, Drug: Pemetrexed | Arm Label: Atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody | Intervention Type: DRUG; Name: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody; Assigned to Arm(s): Atezolizumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)
D: Arm Label: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab | Arm Label: Docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Docetaxel

Answer: A